Multiparametric magnetic resonance imaging (MRI) provides an accurate anatomical assessment of the tumor and its local staging.
Herein, we report a case of intermediate-risk prostatic adenocarcinoma, initially followed on active surveillance, which upgraded from Gleason 7 (3 + 4) to Gleason 8 (4 + 4) on transrectal ultrasound/MRI fusion biopsy after progression of MR spectroscopic findings and review of the role of multiparametric MRI in the follow-up of patients with prostate cancer undergoing active surveillance.
Written by:
Johnson LM, Rothwax JT, Turkbey B, Rais-Bahrami S, Wood BJ, Figg WD, Choyke PL, Merino MJ, Pinto PA. Are you the author?
Molecular Pharmacology Section, Medical Oncology Branch, and Molecular Imaging Program, National Cancer Institute, Bethesda, MD; Urologic Oncology Branch, NCI, NIH, Bethesda, MD; Center for Interventional Oncology, Radiology and Imaging Sciences CC, NIH, Bethesda, MD; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD; Laboratory of Pathology, NCI, NIH, Bethesda, MD.
Reference: J Comput Assist Tomogr. 2014 Apr 11. Epub ahead of print.
doi: 10.1097/RCT.0000000000000069
PubMed Abstract
PMID: 24733004
UroToday.com Prostate Cancer Section
